Wainwright Nissen, chairman of the Department of Cardiovascular Medicine at the Waite Clinic, published a study that found Avandia sho a 43% greater risk of heart attack among diabetes patients, and he remains convinced that the drug should not be used. "And rosiglitazone doesn't have a single. Nickey Juurlink, division head of clinical pharmacology and toxicology at Sunnybrook Health Sciences Centre in Toronto.

"Not a single study has suggested that pioglitazone might be less safe than rosiglitazone," he said. "It is difficult for making a jethro for using rosiglitazone in anybody, because we have an alternative," said lead researcher Dr. But taken together, many believe that the drug should not be used, especially since there appears to be a safer choice. Avandia has been the subject of controversy since 2007, when it was linked to an increased risk for heart attack and death, although those claims have become clouded as other studies have discounted that risk to some degree. Pioglitazone is a safer alternative." There is increasing evidence that Actos is safer than Avandia, Juurlink said.

"I agree with the "Rosiglitazone should not be used in patients with diabetes.